In vivo monoamine oxidase inhibition by d-amphetamine.
D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- / Q000494:pharmacology; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000201:enzymology*; D003042:Cocaine / Q000494:pharmacology; D003342:Corpus Striatum / Q000378:metabolism; D003913:Dextroamphetamine / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D008996:Monoamine Oxidase Inhibitors; D010624:Phenelzine / Q000494:pharmacology; D051381:Rats
D008996:Monoamine Oxidase Inhibitors; D015102:3,4-Dihydroxyphenylacetic Acid; D012369:2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; D000661:Amphetamine; D003042:Cocaine; D006220:Haloperidol; D010624:Phenelzine; D003913:Dextroamphetamine